60 results about "Cobra venom" patented technology

The invention discloses a film agent quickly dissolved in the oral cavity and a preparation method thereof. The film agent consists of the following components in percentage by weight: 0.1 to 70 percent of medicinal active ingredients, 30 to 90 percent of water-soluble film forming material, 2 to 20 percent of plasticizer, 0 to 5 percent of disintegrating agent, and 1 to 20 percent of water, wherein the medicinal active ingredients are selected from modified or non-modified cobra venom, sumatriptan succinate, ergotamine dihydrogen tartrate and lomerizine hydrochloride or flunarizine hydrochloride. The film agent is quick in response, and avoids decomposition in gastrointestinal tracts due to oral administration to reduce the treatment effect. The preparation method is simple, economic and practical, and facilitates industrialized batch production.

The present invention is chicken yoke antibody (IgY) resisting Bengalese cobra venom and its preparation process. The preparation process includes water dilution to extract coarse IgY from chicken yoke, salting out IgY with ammonium sulfate, dissolving the precipitate in PBS, ultrafiltering to desalt, concentrating, anion exchanging chromatographic separation for further purifying IgY, ultrafiltering to desalt, concentrating, and freeze drying. The IgY exhibits single tape of molecular weight 200 KD in non-reductant SDS-PAGE and two tapes of molecular weight 65 KD and 35 KD separately in reductant SDS-PAGE, and has at least 13 dyeing strips of molecular weight 100-0.7 KD on PVDF film for Western Blot detection. The chicken yoke antibody (IgY) resisting Bengalese cobra venom may be used in preparing medicine and health food for preventing and/or treating snake bite, and in preparing reagent for detecting relevant snake venom.

The invention discloses a purification method, an extract and a preparation of cobra venom neurotoxin. The extract of the cobra venom neurotoxin is prepared from cobra crude venom through extraction and purification. A filter membrane filtering method is firstly adopted for removing germs, particles and macromolecular sensitizers in solution, the time and the cost are saved for the subsequent processes, and the safety of products is enhanced; an ion exchange method is adopted for eluting and separating the neurotoxin, and the separation of neurotoxin protein is improved; and finally, acetone is adopted for directly precipitating the cobra venom neurotoxin, and impurities in final products are removed. Compared with the prior art, the extract and the preparation obtained in the invention have the advantages that the product yield, the content and the purity are improved, the adverse reaction of the medicine is effectively reduced, the curative effect is improved, and the quality of products is ensured.

The present invention discloses an anti-tumour snake venom cytotoxin and a production technique thereof, belonging to the fields of biochemistry and biological medicines. The snake venom cytotoxin of the present invention is derived from the prior lyophilized cobra venom powder. In the production technique of the present invention, the lyophilized cobra venom powder is resolved in the known buffer solution, and then on a SP-Sepharose H.P cation exchange column (5.0cm multipled by 29cm), gradiently eluted stage by stage by phosphate buffer and NaC1 at 10ml per tube and the flowing speed of 18ml per minute, a KTA Explorer protein purification system is used to monitor and collect eluting peaks, XII and XIII peaks with cytotoxic effects are collected, and via Source 30RPC reversed phase chromatography, cytotoxin XII and cytotoxin XIII, the molecular weight of which is about 6000 daltons to 7000 daltons and the isoelectric point of which is larger than 10, are respectively obtained. Compared with the purification step of the prior art, the production technique for producing the pure anti-tumour snake venom cytotoxin product without PLA2 has good rapid repeatability and is suitable for expanded production.

The invention provides a method for separating and purifying cobra neurotoxin protein through dual-ion exchange chromatography. The method comprises the following steps of: (1) first separation and purification through ion exchange chromatography, namely, a) dissolution of crude cobra venom, and b) separation and purification through an SP-Sephodex-C25 gel column; and (2) second separation and purification through ion exchange chromatography, namely, a) balance of a SourceS(XK5030) column having a column volume of 500 ml by using 1000 ml of liquid A for future use; and b) SourceS(XK5030) column purification, and then collection of the cobra neurotoxin protein purified twice according to a standard purification chromatogram. The method provided by the invention is scientific and rational in process; and no organic reagent, no high-concentration salt and no protein modification method are used in production, so that the biological activity of cobratide can be maintained to an utmost extent. The method provided by the invention is advanced in process and simple to operate; the production period can be greatly shortened, the production time can be saved and the production cost can be reduced; and the method is completely suitable for an industrial production line.

Detoxified cobra venom and its constituent neurotoxins have been reported to have potent antiviral activity. Others have reported that snake venoms were generally immune stimulants. Recent research has revealed more specific details on the effects of detoxified venoms and isolated alpha-neurotoxins on cells of the immune system. Exposure of the immune cells to these detoxified proteins yields a strong response in the innate immune reaction that represents the immune systems initial response to infectious agents. Of particular relevance is the marked increase in the expression of genes associated with the production of gamma interferon, a potent antiviral agent and regulator of the immune response. The ability to induce this strong innate response has significant application to those with weakened immune systems where their ability to fight infection has been compromised. It also has the potential application to act as a method to protect individuals from contagious infectious agents as a substitute for anti-viral vaccines.

The invention relates to a venin-sourced demulcent CTXn, and a purification method and applications thereof. The invention is characterized in that (1) the molecular weight of the CTXn is 6697.429 Da; (2) and the amino acid sequence of the CTXn is described as the sequence list SEQ ID No.1. The preparation method comprises the following steps of: using a Zhoushan cobra venom sample; carrying out the CTXn separation and purification on the Zhoushan cobra venom sample; primary-screening to select a component III for next step of ion exchange; carrying out the ion exchange on the component III through a quick-purification technique exploitation system by using a filler to obtain a single-virulence polypeptide CTXn, desalting with a G-50 prepacked column, and freeze-drying; and measuring the molecular weight and the amino acid sequence of the CTXn. The CTXn of the invention has favorable demulcent function on somatalgia and visceralgia caused by nociceptive stimulus as well as pains caused by addiction to morphine, has the characteristics of obvious drug effect and low toxic or side effect, is beneficial to large-scale production, and has wide application prospects in the aspect of analgesic development.

The invention discloses a cobra-venom factor and cobra-venom neurotoxin combined separation and purification method which includes the following steps: firstly the cobra-venom crude liquid is processed with centrifugation treatment at low temperature and high speed, and then small molecule substances, low molecular peptides and the like contained in the cobra-venom crude liquid are removed through a 3KDa ultrafiltration membrane. The two chromatography processes respectively adopt a CM-Sephrose. FF chromatographic column and a Superdex.200 gel chromatographic column; and cobra-venom neurotoxin and cobra-venom factor which are two active ingredients can be obtained in one production process. The method has the characteristics that the cobra-venom factor and the cobra-venom neurotoxin can be separated, the application efficiency of the cobra-venom is effectively improved, the purities of the products are improved and the method is suitable for industrial production.

The invention discloses application of cobra venom in preparation of a medicament for treating lung inflammatory disease and pulmonary fibrosis. Animal experiment proves that Chinese cobra venom can alleviate acute endotoxin poisoning symptom within a range of 10-3000mug/kg, particularly has obvious therapeutic action on lung inflammatory disease caused by endotoxin, and can be used for alleviating inflammatory cell infiltration, alveolar septum thickening, and focal atelectasis and emphysema. Repeated small dose of endotoxin can result in pulmonary fibrosis, the cobra venom can significantly alleviate pulmonary fibrosis symptom and reduce alveoli damage and collagen hyperplasia. Naturally-modified Chinese cobra venom and physically-modified Chinese cobra venom have similar actions, but the physically-modified Chinese cobra venom has better action. Used for treating lung inflammatory disease, the Chinese cobra venom has the advantages of low dose, safety, capability of being orally administrated, injected, and administered through oral mucous membrane and skin and the like.

This invention discloses a mixture of cobra venom with Chinese herb extracts and its applications. , of which the weight portion is 0.004-0.006 and 3-6 respectively. The said Chinese herb extracts are prepared according to the following weight ratios: Succinum (13~17),Caulis Sargentodoxae (8~12),Rhizoma Curculiginis (8~12),Rhizoma erubescens Schott (6~10),Scolopendra (2~6),Dysosma versipellis (6~10 ),Gekko (8~12),Radix Cynanchi Paniculati (6~10),scorpion (8~12),Rhizoma Zingiberis Recens (8~12),Radix Notoginseng (8~12),Herba Lobellae Chinensis (15~25),Ganoderma lucidum (15~25),Cordyceps sinensis (3~7),Radix Glycyrrhizae (25~35),Paris polyphylla (8~12).The mixture of Cobra Venom with Chinese herb extracts in this invention has a remarkable curative effect on cancer. It is able to satisfy people's requirements and worth promoting its application.

The invention discloses a production method of a growth factor supported porous biologic ceramic artificial bone scaffold, and belongs to the field of medical science and biomedical engineering. Qualitative and quantitative detection of a cobra venom nerve growth factor (NFG) adsorbed through a biphasic calcium phosphate ceramic (BCP) artificial bone scaffold and artificial bone scaffold function detection prove that the NGF supported BCP is in favor of realizing osteoblast proliferation and directed differentiation. The NGP supported BCP has a good ossification promotion effect, provides a possible method for producing osteoblast in vitro culture scaffolds, and makes researches of bioengineering materials be possible.

The invention discloses an application of cobra venom nerve growth factor in preparing the medicine of preventing and treating liver fibrosis and liver cirrhosis. The study indicates that the cobra venom nerve growth factor has the effects of inducing apoptosis in HSC-T6, resisting liver fibrosis at the cellular level and in animals, and effectively inhibiting or reducing the degree of hepatic fibrosis. Taking the cobra venom nerve growth factor as a medicinal main active ingredient, the application has the advantages of remarkable efficacy, fast effect, safety and efficacy, few side effects. The cobra venom nerve growth factor is an ideal medicine of preventing and treating liver fibrosis and liver cirrhosis.

The invention relates to the technical field of medicaments, and particularly relates to an application of cobra venom in preparation of a medicament for treating chronic obstructive pulmonary disease. The cobra venom has an obvious treatment effect on chronic obstructive pneumonia induced by repeatedly contacting LPS (lipopolysaccharide) for a long term, and can effectively improve the pathological injury of lung tissues. The Chinese cobra venom not only can reduce the lung coefficient of a chronic obstructive pneumonia mouse, but also can effectively protect the lung tissues. The cobra venom not only can inhibit the degradation of IkB-alpha in the lung tissues of a sick mouse, but also can lower the expression of TGF-beta1. The cobra venom not only can reduce the TNF-alpha level, but also can reduce the level of an inflammatory factor IL-1.

The invention discloses a natural medical composition for treating hepatitis B. The medical composition is prepared from the following components in percentage by weight: 10-20g of radix phytolaccae, 0.02-0.03g of cobra-venom, 2-3g of lecithin, 60-80g of cordyceps polysaccharide, 50-60g of honey, 60-70g of syrupus simplex, 0.5-0.6g of hydroxy ethyl and 0.8g of sodium bicarbonate. The medicine of the invention decreases the cost of a traditional hepatitis B treatment scheme, simultaneously lessens the toxic and side effects on the medicine on human bodies, improves the spectral sensitivity and the stability and can solve the problem of instable medical effect of traditional Chinese medicines.

The invention discloses a purification preparation method of cobra venom CTX (cytotoxin)-4N. According to the method, a DEAE-SepharoseCL-6B anion exchange column is firstly used; then, a SephadexG-50 gel chromatographic column and a Macro-prep High S cation exchange column are used for respective separation; after separation in each time, the peak, with the highest activity, of the cobra venom CTX-4N is selected as a sample of the subsequent separation. Research shows after the method is used, CTX-4N with electrophoresis purity can be obtained; the purity is high; the activity is high. HSC-T6 proliferation inhibition and apoptosis experiments prove that the CTX-4N has a killing effect on HSC-T6 cells; the condition that the CTX-4N has the anti-hepatic fibrosis effect in the hepatic fibrosis development process is prompted; important medicinal values are realized.

The invention relates to the field of medicine, and particularly provides application of cobra venom or an extract thereof to preparation of a medicament for reducing uric acid and/or resisting to gouty arthritis. According to the invention, the cobra venom can effectively reduce the blood uric acid level of a hyperuricemic mouse, meanwhile, has an obvious improvement effect on the gouty arthritis, and can repair the joint injury caused by sodium urate deposition, reduce the joint swelling rate, improve the joint synovial tissue thickening condition, reduce inflammatory cell infiltration, protect cartilage cells; and clinical experiments show that cobra neurotoxin can quickly eliminate subcutaneous gout calculi of gout patients, lumps disappear after the cobra venom is injected into the patients for three days, and no side effect exists. In conclusion, the Chinese cobra venom has the effect of repairing gouty arthritis while reducing uric acid, and can be used as a medicament for treating gout.

The invention discloses an anticoagulant drug based on cobra venom PIII type metalloprotease. The cobra venom PIII type metalloprotease is extracted from snake venom of naja atra and then purified. The metalloprotease is single chain glycoprotein. The structure analysis shows that metalloprotease has three structural domains: metalloprotease structural domain, disintegrin like structural domain, and cysteine enriched structural domain, and belongs to PIII type cobra venom metalloprotease. The metalloprotease is named as Atrase A and Atrase B; and the sequences of Atrase A and Atrase B are represented by SEQ ID No.1 and SEQ ID No.2 respectively. Target protein and anticoagulant drugs thereof have multiple anticoagulant effects: preventing multiple blood coagulation factors; reducing fibrinogen level; preventing platelet aggregation; and preventing complement so as to relieve abnormal blood coagulation caused by inflammation.

The invention discloses a method for purifying cobra venom and its products. The invention provides a method for purifying cobra venom, which comprises the following steps: (1) performing cation exchange chromatography on a phosphate buffer containing the cobra venom to obtain an eluent A containing an active ingredient; wherein the phosphate buffer containing the cobra venom includes the cobra venom and a phosphate buffer solution; (2) performing complex mode chromatography on the eluent A containing the active ingredient to obtain an eluent B containing the active ingredient; and (3) desalting the eluent B containing the active ingredient to obtain the active ingredient. The purifying method has the advantages of simple process, easy industrialization, and low cost, and obtained producthas the advantages of high purity and low content of related substances.

The invention relates to the primary structure of Yikang protein, a diseased snakes disintegrins mutant anti-human platelet aggregation medicament, which concerns the amino acid residue sequence and the corresponding nucleotide sequence of the disintegrins mutant protein from recombinant agkistrodotoxin of cobra-venom, and the actions for inhibiting human platelet aggregation, preventing and treating thrombus, wherein the protein of low molecular weight consisting of 73 amino acid residues contains 12 cysteine residues and form 6 disulfide bonds. The beneficial effects of the invention include, the action for inhibiting platelet aggregation is achieved, and the suppression to blood vessel neogenesis is avoided.

The invention discloses a high-titer anti-cobra neurotoxin serum and a preparation method thereof. The preparation method comprises the following steps: firstly, reducing neurotoxicity of cobra venom; then, embedding the cobra venom in polyacrylamide gel; and finally, grinding neurotoxin-containing gel, performing immune injection on rabbits to obtain antiserum, and performing cryopreservation. In the invention, different doses of cobra venom are adopted; the neurotoxicity is reduced by heating, SDS and beta-mercaptoethanol treatment; the emulsification is replaced with polyacrylamide gel embedding, so as to ensure healthy survival of immunized animals, reduce production cost of he antiserum, and prepare high-titer antiserum.